Growth hormone secretagogues: Past, present and future

IDrugs

Volumn 5, Issue 8, 2002, Pages 804-814

  Fehrentz, Jean Alain ^a   Martinez, Jean ^a   Boeglin, Damien ^a   Guerlavais, Vincent ^a   Deghenghi, Romano ^b  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b Ardana   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (2 AMINO 2 METHYLPROPIONYLAMINO) 3 (1H INDOL 3 YL)PROPIONYL] 3 BENZYL 3 PIPERIDINECARBOXYLIC ACID ETHYL ESTER; 3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DIPEPTIDE DERIVATIVE; EP 01572; EP 51389; ESTROGEN DERIVATIVE; GHRELIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; GROWTH HORMONE SECRETAGOGUE; HEXARELIN; IBUTAMOREN; IPAMORELIN; L 162752; LACTAM DERIVATIVE; PIPERIDINE DERIVATIVE; RECOMBINANT GROWTH HORMONE; SERTRALINE; SM 130686; TABIMORELIN; UNCLASSIFIED DRUG;

BINDING AFFINITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HUMAN; NONHUMAN; OBESITY; OSTEOPOROSIS; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 0037501202     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Bowers CY, Chang J, Momany F, Folkers K: Effects of the enkephalins and enkephalin analogs on release of pituitary hormones in vitro. In: Molecular Endocrinology. MacIntyne I (Ed), Elsevier, Amsterdam, the Netherlands (1977):287-292.
2. Bowers CY, Momany FA, Reynolds GA, Hong A: On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology (1984) 114:1537-1545. First synthetic compounds (GHRPs) that elicit the release of GH in vitro and in vivo through a GHRH/SRIF independent pathway.
3. Ilson BE, Jorkasky DK, Curnow RT, Stote RM: Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects. J Clin Endocrinol Metab (1989) 69:212-214. The GHRPs exhibit a GH-releasing activity in humans.
4. Deghenghi R, Cananzi MM, Torsello A, Battisti C, Muller EE, Locatelli V: GH-releasing activity of Hexaredin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci (1994) 54:1321-1328.
5. Imbimbo BP, Mant T, Edwards M, Amin D, Dalton N, Boutignon F, Lenaerts V, Wüthrich P, Deghenghi R: Growth hormone-releasing activity of Hexaredin in humans. A dose-response study. Eur J Clin Pharmacol (1994) 46:421-425.
6. Cheng K, Chan WW, Butler B, Wei L, Schoen WR, Wyvratt MJ Jr, Fisher MH, Smith RG: Stimulation of growth hormone release from rat primary pituitary cells by L-692,429, a novel non-peptidyl GH secretagogue. Endocrinology (1993) 132:2729-2731. First low molecular weight non-peptidyl compound (GHS) able to stimulate GH secretion.
7. Pong SS, Chaung LY, Dean DC, Nargund RP, Patchett AA, Smith RG: Identification of a new G-protein-linked receptor for growth hormone secretagogues. Mol Endocrinol (1996) 10:57-61.
8. Smith RG, Pong SS, Hickey G, Jacks T, Cheng K, Leonard R, Cohen CJ, Arena JP, Chang CH, Drisko J, Wyvratt M, Fisher M, Nargund R, Patchett A: Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Recent Prog Horm Res (1996) 51:261-285.
9. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenbaum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C et al.: A receptor in pituitary and hypothalamus and functions in growth hormone release. Science (1996) 273:974-977. Discovery of a receptor in pituitary and hypothalamus thata binds to GHSs and is implicated in GH release.
10. McKee KK, Tan CP, Palyha OC, Liu J, Feighner SD, Hreniuk DL, Smith RG, Howard AD, Van Der Ploeg LH: Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors. Genomics (1997) 46:426-434.
11. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature (1999) 402:656-660 Isolation from stomach and characterization of ghrelin, the endogenous ligand of the GHS receptor.
12. Strobl JS, Thomas MJ: Human growth hormone. Pharmacol Rev (1994) 46:1-34.
13. Torosian MH: Growth hormone and prostate cancer growth and metastasis in tumor-bearing animals. J Pediatr Endocrinol (1993) 6:93-97.
14. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Matts DE: Effects of human growth hormone in men over 60 years old. N Engl J Med (1990) 323:1-6.
15. Papadakis MA, Grady D, Black D, Tierney MJ, Gooding GA, Schambelan M, Grunfeld C: Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med (1996) 124:708-716.
16. Welle S, Thornton C, Statt M, McHenry B: Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab (1996) 81:3239-3243.
17. Korbonits M, Bustin SA, Kojima M, Jordan S, Adams EF, Lowe DG, Kangawa K, Grossman AB: The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary gland and other neuroendocrine tumors. J Clin Endocrinol Metab (2001) 86:881-887.
18. Mori K, Yoshimoto A, Takaya K, Hosoda K, Ariyasu H, Yahata K, Mukoyama M, Sugawara A, Hosoda H, Kojima M, Kangawa K, Nakao K: Kidney produces a novel acylated peptide, ghrelin. FEBS Lett (2000) 486:213-216.
19. Hattori N, Saito T, Yagyu T, Jiang BH, Kitagawa K, Inagaki C: GH, GH receptor, GH secretagogue receptor, and ghrelin expression in human T cells, B cells, and neutrophils. J Clin Endocrinol Metab (2001) 86:4284-4291.
20. Kanamoto N, Akamizu T, Hosoda H, Hataya Y, Ariyasu H, Takaya K, Hosoda K, Saijo M, Moriyama K, Shimatsu A, Kojima M, Kangawa K, Nakao K: Substantial production of ghrelin by a human medullary thyroid carcinoma cell line. J Clin Endocrinol Metab (2001) 86:4984-4990.
21. Volante M, Allia E, Gugliotta P, Fumaro A, Broglio F, Deghenghi R, Muccioli G, Ghigo E, Papotti M: Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab (2002) 87:1300-1308.
22. Woods SC, Seeley RJ, Porte D Jr, Schwartz MW: Signals that regulate food intake and energy homeostasis. Science (1998) 280:1378-1383.
23. Abbott CR, Rossi M, Wren AM, Murphy KG, Kennedy AR, Stanley SA, Zollner AN, Morgan DG, Morgan I, Ghatei MA, Small CJ, Bloom SR: Evidence o an orexigenic role for cocaine- and amphethamine-regulated transcript after administration into discrete hypothalamic nucleic. Endocrinology (2001) 142:3457-3463.
24. Shimon I, Yan X, Melmed S: Human fetal pituitary expresses functional growth hormone-releasing peptide receptors. J Clin Endocrinol Metab (1998) 83:174-178.
25. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S: A role for ghrelin in the central regulation of feeding. Nature (2001) 409:194-198. Ghrelin is not only a GHS, but also interacts in the central regulation of feeding
26. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Nijima A, Fujino MA, Kasuga M: Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology (2001) 120:337-345.
27. Tschöp M, Smiley DL, Heiman ML: Ghrelin induces adiposity in rodents. Nature (2000) 407:908-913.
28. Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, Hosoda H, Kojima M, Kangawa K: Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun (2000) 276:905-908. Intravenous administrations of rat ghrelin increased gastric acid secretion and gastric motility. The maximum response in gastric acid secretion was almost equipotent to that of histamine. These results suggest that ghrelin may play a physiological role in the vagal control of gastric function in rats.
29. Date Y, Nakazato M, Murakami N, Kojima M, Kangawa K, Matsukura S: Ghrelin acts in the central nervous system to stimulate gastric acid secretion. Biochem Biophys Res Commun (2001) 280:904-907.
30. Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, Ghigo E: Endocrine activities of ghrelin, a natural growth hormone segretagogue (GHS), in humans: Comparison and interactions with Hexaredin, a non-natural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab (2001) 86:1169-1174. Ghrelin stimulates GH release and ACTH, PRL, cortisol, aldosterone and epinephrine secretion, and shows multiple-endocrine activity.
31. Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H, Hayashi Y, Kangawa K: Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integrative Comparative Physiol (2001) 280:R1483-R1487.
32. Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M, Mori K, Komatsu Y, Usui T, Shimatsu A, Ogawa Y, Hosoda K, Akamizu T, Kojima M, Kangawa K, Nakao K: Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab (2000) 85:4908-4911.
33. Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML: Circulating ghrelin levels are decreased in human obesity. Diabetes (2001) 50:707-709.
34. Hosoda H, Kojima M, Matsuo H, Kangawa K: Ghrelin and des-acyl ghrelin: Two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun (2000) 279:909-913.
35. 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland. J Endocrinol Invest (2001) 24:RC7-RC9.
36. Bowers CY: Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab (2001) 86:1464-1469.
37. Bednarek MA, Feighner SD, Pong SS, McKee KK, Hreniuk DL, Silva MV, Warren VA, Howard AD, Van Der Ploeg LH, Heck JV: Structure-function studies on the new growth hormone-releasing peptide, ghrelin: Minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J Med Chem (2000) 43:4370-4376.
38. Matsumoto M, Kitajima Y, Iwanami T, Hayashi Y, Tanaka S, Minamitake Y, Hosoda H, Kojima M, Matsuo H, Kangawa K: Structural similarities of ghrelin derivatives to peptidyl growth hormone secretagogues. Biochem Biophys Res Commun (2001) 284:655-659.
39. Torsello A, Ghe C, Bresciani E, Catapano F, Ghigo E, Deghenghi R, Locatelli V, Muccioli G: Short ghrelin peptides neither displace ghrelin binding in vitro nor stimulate GH release in vivo. Endocrinology (2002) 143:1968-1971.
40. Cassoni P, Papotti M, Ghe C, Catapano F, Sapino A, Graziani A, Deghenghi R, Reissmann T, Ghigo E, Muccioli G: Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab (2001) 86:1738-1745.
41. Muccioli G, Tschöp M, Papotti M, Deghenghi R, Heiman M, Ghigo E: Neuroendocrine and peripheral activities of ghrelin: Implications in metabolism and obesity. Eur J Pharmacol (2002) 440:235-254.
42. Ravussin E, Tschöp M, Morales S, Bouchard C, Heiman ML: Plasma ghrelin concentration and energy balance: Overfeeding and negative energy balance studies in twins. J Clin Endocrinol Metab (2001) 86:4547-4551.
43. Tschöp M, Wawarta R, Riepl RL, Friedrich S, Bidlingmaier M, Landgraf R, Flowaczny C: Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest (2001) 24:RC19-RC21.
44. Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML: Circulating ghrelin levels are decreased in human obesity. Diabetes (2001) 50:707-709.
45. Toshinai K, Mondal MS, Nakazato M, Date Y, Murakami N, Kojima M, Kangawa K, Matsukura S: Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem Biophys Res Commun (2001) 281:1220-1225.
46. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, Suda M, Koh T, Natsui K, Tayooka S, Shirakami G, Usui T, Shimatsu A, Doi K, Hosoda H, Kojima M, Kangawa K, Nakao K: Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab (2001) 86:4753-4758.
47. Cummings DE, Pumell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS: A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes (2001) 50:1714-1719.
48. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhilo WS, Ghatei MA, Bloom SR: Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab (2001) 86:5992.
49. Lawrence CB, Snape AC, Baudoin FM, Luckman SM: Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology (2002) 143:155-162.
50. Jeffery PL, Herington AC, Chopin LK: Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. J Endocrinol (2002) 172:R7-R11. Ghrelin and GHSRs are expressed in some cancer cell lines, leading to the question of what their role might be in these cells and whether it represents a new potential target for therapy.
51. Deghenghi R, Papotti M, Ghigo E, Muccioli G: Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland. J Endocrinol Invest (2001) 24:RC1-RC3.
52. Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F: Growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab (1994) 78-693-698.
53. Loche S, Cambiaso P, Merola B, Colao A, Faedda A, Imbimbo BP, Deghenghi R, Lombardi G, Cappa M: The effect of Hexarelin on growth hormone (GH) secretion in patients with gH deficiency. J Clin Endocrinol Metab (1995) 80:2692-2696.
54. Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A: Intranasal administration of the GHRP Hexarelin accelerates growth in short children. Clin Endocrinol (1995) 43:631-635.
55. Loche S, Cambiaso P, Carta D, Setzu S, Imbimbo BP, Borrelli P, Pintor C, Cappa M: The growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects. J Clin Endocrinol Metab (1995) 80:674-678.
56. Bellone J, Aimaretti G, Bartolotta E, Benso L, Imbimbo BP, Lenhaerts V, Deghenghi R, Camanni F, Chicago E: Growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, before and during puberty. J Clin Endocrinol Metab (1995) 80: 1090-1094.
57. Massoud AF, Hindmarsh PC, Brook CG: Hexarelin-induced growth hormone, cortisol, and prolactin release: A dose-response study. J Clin Endocrinol Metab (1996) 81:4338-4341.
58. Ghigo E, Arvat E, Ramunni J, Colao A, Gianotti L, Deghenghi R, Lombardi G, Camanni F: Adrenocorticotropin- and cortisol-releasing effect of Hexarelin, a synthetic growth hormone releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab (1997) 82:2439-2444.
59. Arvat E, Ramunni J, Bellone J, Di Vito L, Baffoni C, Broglio F, Deghenghi R, Bartolotta E, Ghigo E: The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations. Eur J Endocrinol (1997) 137:635-642.
60. Rossoni G, De Gennaro Colonna V, Bernareggi M, Polvani GL, Müller EE, Berti F: Protectant activity of Hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. J Cardiovasc Pharmacol (1998) 32:260-265.
61. Bodart V, Bouchard JF, McNicoll N, Escher E, Carriere P, Ghigo E, Sejlitz T, Sirois MG, Lamontagne D, Ong H: Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circ Res (1999) 85:796-802.
62. Muccioli G, Broglio F, Valetto MR, Ghe C, Catapano F, Graziani A, Papotti M, Bisi G, Deghenghi R, Ghigo E: Growth hormone-releasing peptides and the cardiovascular system. Ann Endocrinol (2000) 61:27-31.
63. Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Escher E, Silverstein RL, Lamontagne D, Ong H: CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res (2002) 90:844-849.
64. Maccario M, Veldhuis JD, Broglio F, Vito LD, Arvat E, DeghenghiR, Ghigo E: Impact of two or three daily subcutaneous injections of Hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans. Eur J Endocrinol (2002) 146:310-318.
65. Torsello A, Luoni M, Schweiger F, Grilli R, Guidi M, Bresciani E, Deghenghi R, Muller EE, Locatelli V: Novel Hexarelin analogs stimulate feeding in the rat through a mechanism not involving growth hormone release. Eur J Pharmacol (1998) 360:123-129.
66. Ghe C, Cassoni P, Catapano F, Marrocco T, Deghenghi R, Ghigo E, Muccioli G, Papotti M: The antiproliferative effect of synthetic peptidyl GH secretagogues in human CALU-1 lung carcinoma cells. Endocrinology (2002) 143:484-491.
67. Deghenghi R: Impervious peptides as GH secretagogues. In: Growth Hormone Secretagogues. Ghigo E, Boghen M, Casanueva FF, Dieguez C (Eds), Elsevier Science BV, Amsterdam, the Netherlands (1999):19-24.
68. Broglio F, Boutignon F, Benso A, Gottero C, Prodam F, Arvat E, Ghe C, Catapano F, Torsello A, Locatelli V, Muccioli G, Guerlavais V, Boeglin D, Fehrentz JA, Martinez J, Ghigo E, Deghenghi R: EP1572: A novel peptido-mimetic GH secregtagogue with potent and selective GH-releasing activity in man. J Endocrinol Invest (2002) in press.
69. Hickey G, Jacks T, Judith F, Taylor J, Schoen WR, Krupa D, Cunningham P, Clark J, Smith RG: Efficacy and specificity of L-692,429, a novel nonpeptidyl growth hormone secretagogue in beagles. Endocrinology (1994) 134:695-701.
70. Leung KH, Cohn DA, Miller RR, Doss MA, Stearns RA, Simpson RE, Feeney WP, Chiu SHL: Pharmacokinetics and disposition of L-692,429, a novel non-peptidyl growth hormone secretagogue, in preclinical species. Drug Metab Dispos (1996) 24:753-760.
71. Gertz BJ, Barrett JS, Eisenhandler R, Krupa DA, Wittreich JM, Seibold JR, Schneider SH: Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. J Clin Endocrinol Metab (1993) 77: 1393-1397.
72. Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DBR, Cheng K, Chan WWS, Butler B, Hickey G, Jack T, Schleim K, Pong SS, Chaung LYP, Chen HY, Frazier E, Leung KH, Chiu SH, Smith RG: Design and biological activities of L-163,191 (MK-0677): A potent, orally active growth hormone secretagogue. Proc Natl Acad Sci USA (1995) 92:7001-7005. MK-0677 is the first orally active GHS. Its labeled derivative has allowed the isolation and characterization of the receptor GHS-R 1a.
73. Chen MH, Steiner MG, Patchett AA, Cheng K, Wei L, Chan WWS, Butler B, Jacks TM, Smith RG: Analogues of the orally active growth hormone secretagogue L-162,752. Bioorg Med Chem Lett (1996) 6:2163-2168.
74. Jacks T, Smith R, Judith F, Schleim K, Frazier E, Chen H, Krupa D, Hora D, Nargund R, Patchett A, Hickey G: MK-0677, a potent, a novel, orally active growth hormone (GH) secregtagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Endocrinology (1996) 137:5284-5289.
75. Copinschi G, Van Onderbergen A, L'Hermite-Baleriaux M, Mendel CM, Caufriez A, Leproult R, Bolognese JA, De Smet M, Thorner MO, Van Cauter E: Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab (1996) 81:2776-2782.
76. Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, Skiles EH, Pezzoli SS, Hartman ML, Veldhuis JD, Gormley GJ, Thorner MO: Stimulation of the growth hormone (GH) insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab (1996) 81:4249-4257.
77. Svensson J, Lonn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus L, Sjostrom L, Bengtsson BA: Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass and energy expenditure. J Clin Endocrinol Metab (1998) 83:362-369.
78. Svensson J, Carlsson B, Carlsson LM, Jansson JO, Bengtsson BA: Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677. Clin Endocrinol (1999) 50:451-456.
79. Svensson J, Jansson JO, Ottosson M, Johansson G, Taskinen MR, Wiklund O, Bengtsson BA: Treatment of obese subjects with the oral growth hormone secretogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein A. J Clin Endocrinol Metab (1999) 84:2028-2033.
80. Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ: Oral administration of the growth secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. J Bone Miner Res (1999) 14:1182-1188.
81. Svensson J, Ohlsson C, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Baylink D, Mohan S, Bengtsson BA: Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males. J Bone Miner Res (1998) 13:1158-1166.
82. Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ: Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab (2001) 86:1116-1125.
83. Yang L, Morriello G, Patchett AA, Leung K, Jacks T, Cheng K, Schleim KD, Feeney W, Chan WWS, Chiu SHL, Smith RG [2(R)-(2-amino-2-methylpropionylamino)-3-benzylpiperidine-3(S)-carboxylic acid ethyl ester (L-163,540): A potent, orally bioavailable, and short-duration growth hormone secretagogue. J Med Chem (1998) 41:2439-2441.
84. Ye Z, Gao Y, Bakshi RK, Chen MH, Rohrer SP, Feighner SD, Pong SS, Howard AD, Blake A, Birzin ET, Locco L, Parmar RM, Chan WWS, Schaeffer JM, Smith RG, Patchett AA, Nargund RP: Modelling directed design and biological evaluation of quinazolines as non-peptidic growth hormone secretagogues. Bioorg Med Chem Lett (200) 10:5-8.
85. Palucki BL, Feighner SD, Pong S-S, McKee KK, Hreniuk DL, Tan C, Howard AD, Van Der Ploeg LHY, Patchett AA, Nargund RP: Spiro(indoline-3,4′-piperidine) growth hormone secretagogues as ghrelin mimetics. Bioorg Med Chem Lett (2001) 11:1955-1957.
86. Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH: Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol (1998) 139:552-561.
87. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H: Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res (1999) 9:106-113.
88. Ankersen M, Johansen NL, Madsen K, Hansen BS, Raun K, Nielsen KK, Thogersen H, Hansen TK, Peschke B, Lau J, Lundt BF, Andersen PH: A new series of highly potent hormone-releasing peptides derived from ipamorelin. J Med Chem (1998) 41:3699-3704.
89. Hansen TK, Ankersen M, Hansen BS, Raun K, Nielsen KK, Lau J, Peschke B, Lundt BF, Thogersen H, Johansen NL, Madsen K, Andersen PH: Novel orally active growth hormone secretagogues. J Med Chem (1998) 41:705-3714.
90. Ankersen M, Hansen BS, Hansen TK, Lau J, Peschke B, Madsen K, Johansen NL: Demonstration of the strength of focused combinatioral libraries in SAR optimisation of growth hormone secretagogues. Eur J Med Chem (1999) 34:783-790.
91. Hansen BS, Rau K, Nielsen KK, Johansen PB, Hansen TK, Peschke B, Lau J, Andersen PH, Ankersen M: Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol (1999) 141:180-189.
92. Hansen TK, Schlienger N, Hansen BS, Anderson PH, Bryce MR: Synthesis of piperazinones and their application in constrained mimetics of the growth hormone secretagogue NN703. Tetrahedron Lett (1999) 40:3651-3654.
93. Hansen TK, Ankersen M, Raun K, Hansen BS: Highly potent growth hormone secretagogues: Hybrids of NN703 and ipamorelin. Bioorg Med Chem Lett (2001) 11:1915-1918.
94. Peschke B, Ankersen M, Bauer M, Hansen TK, Hansen BS, Nielsen KK, Raun K, Richter L, Westergaard L: The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency. Eur J Med Chem (2002) in press.
95. Tokugana T, Hume WE, Umezome T, Okazaki K, Ueki Y, Kumagai K, Hourai S, Nagamine J, Seki H, Taiji M, Noguchi H, Nagata R: Oxindole derivatives as orally active potent growth hormone secretagogues. J Med Chem (2001) 44:4641-4649.
96. Nagamine J, Nagata R, Seki H, Nomura-Akimaru N, Ueki Y, Kumagai K, Taiji M, Noguchi H: Pharmacological profile of a new orally active growth hormone secretagogue SM-130686. J Endocrinol (2001) 171:481-489.
97. Merck & Co Inc (Patchett AA, Yang L, Chen M-H, Nargund RP, Tata JR, Johnton DBR:) Spiropiperidines and homologs which promote release of growth hormone. WO-09413696 (1994). First patent describing low molecular weight and non-peptidyl compounds able to stimulate GH release.
98. Genentech Inc (Somers TC, Elias KA, Clark RG, McDowell RS, Stanley MS, Burnier JP, Rawson TE) Low molecular weight peptidomimetic growth hormone secretagogues. WO-09615148 (1996).
99. Eli Lilly & Co (Dodge JA, Hipskind PA:) 2-acylaminopropanamides as growth hormone secretagogues. WO-09706803 (1997).
100. Pfizer Inc (Carpino PA, Jardine DP, Lefker BA, Ragan JA): Growth hormone secretagogues. WO-09724369 (1997).
101. Arch Development Corporation (Van Cauter E, Copinschi G): Sleep quality improvement using a growth hormone secretagogue. US-06071926 (2000).
102. Pfizer Inc (Griffith DA, Bronk BS): Dipeptide derivatives. US-06194578 (2001).
103. Pfizer Inc (Carpino PA, Griffith DA, Lefker BA): Dipeptide derivatives as growth hormone secretagogues. US-06251902 (2001).
104. Pfizer Inc (Fossa AA:) Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues. US-20010041673 (2001).
105. Pfizer Inc (Busch FR, Lefker BA, Pan LC): Use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease. US-20020013320 (2002).
106. Pfizer Inc (Busch FR, McKowan WW:) Combination of growth hormone secretagogues and antidepressants. US-20020002137 (2002).
107. Eli Lilly & Co (Kauffman RF, Palkowitz AD:) Treatment of congestive heart failure with growth hormone secretagogues. US-06329342 (2001).
108. Novo Nordisk A/S (Andersen MB, Hansen BS, Raun K, Tullin S, Thim L:) Use of compounds for the regulation of food intake. WO-00156592 (2001).
109. Zentaris AG (Martinez J, Fehrentz J-A, Guerlavais V): Growth hormone secretagogues. WO-00196300 (2001).